ArticleScientific reports2026
Diagnostic performance of kinetic parameters of ultrafast breast MRI and their associations with immunohistopathological findings of breast carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to assess diagnostic values of kinetic parameters in ultrafast dynamic contrast magnetic resonance imaging. The diagnostic performance of ultrafast kinetic parameters (time to enhancement [TTE], maximum slope [MS], time to peak, peak enhancement [PE], and wash-in slope [WIS]), and their correlations with the immunohistopathological findings of breast cancer were evaluated for 101 histologically proven breast lesions. We found that the areas under the curves of five ultrafast kinetic parameters in masses (0.69-0.81) and for MS, PE, and WIS in non-mass enhancement (NME) (0.91-0.94) were comparable to those of Breast Imaging Reporting and Data System (BI-RADS) categorizations (mass: 0.85, NME: 0.83) without statistically significant differences. Values of ultrafast kinetic parameters differed significantly according to invasiveness (invasive vs. non-invasive: TTE, p = 0.029; MS, p = 0.040; PE, p = 0.032; and WIS, p = 0.009), immunohistopathological findings (high vs. low Ki-67: TTE, p = 0.020; MS, p = 0.004; PE, p = 0.003; and WIS, p < 0.001), hormone receptor (negative vs. positive: MS, p = 0.033; and WIS, p = 0.042), and triple-negative status (triple-negative vs. non-triple-negative: MS, p = 0.028; and WIS, p = 0.011) in breast cancer. In conclusion, ultrafast kinetic parameters demonstrate diagnostic performance comparable to that of BI-RADS categories for both mass and NME and may be associated with the immunohistopathological findings of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.